Objective To determine the association of nirmatrelvir/ritonavir (NMV/r) with hospitalization
or death within 30 days as compared with untreated controls previously uninfected and …

Background Studies have established the short-term efficacy of nirmatrelvir–ritonavir in
managing COVID-19, yet its effect on post-COVID-19 condition, especially in patients …

Background Lopinavir-ritonavir is a repurposed drug for coronavirus disease-2019 (COVID-
19). In this study, a pooled effect of lopinavir-ritonavir on mortality, virological cure …

Background Using a retrospective cohort study design, we aimed to evaluate the
effectiveness of molnupiravir and nirmatrelvir/ritonavir in patients with SARS-CoV-2 who …

Purpose: To provide the latest evidence on the efficacy and safety of lopinavir/ritonavir
compared to other treatment options for COVID-19. Methods: We searched PubMed …

Regardless of vaccination status, progression to severe coronavirus disease 2019 (COVID‐
19) is still a relevant cause of morbidity among immunocompromised patients. Despite the …

Objectives Effective and widely available therapies are still needed for outpatients with
COVID-19. We aimed to evaluate the efficacy and safety of lopinavir/ritonavir (LPV/r) for …

Oral nirmatrelvir plus ritonavir (Paxlovid™) is an effective treatment option for coronavirus
disease 2019 (COVID-19), the illness caused by severe acute respiratory syndrome …

Nirmatrelvir-ritonavir for COVID-19 | CMAJ Skip to main content Main menu Home Content
Current issue Past issues Early releases Collections Sections Blog Infographics & illustrations …

This network meta-analysis compared the clinical efficacy and safety of anti-viral agents for
the prevention of disease progression among non-hospitalized patients with COVID-19 …